333 related articles for article (PubMed ID: 30781867)
1. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C
Twarog C; Fattah S; Heade J; Maher S; Fattal E; Brayden DJ
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781867
[TBL] [Abstract][Full Text] [Related]
2. A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C
Twarog C; Liu K; O'Brien PJ; Dawson KA; Fattal E; Illel B; Brayden DJ
Eur J Pharm Biopharm; 2020 Jul; 152():95-107. PubMed ID: 32387703
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.
Tran H; Dogra M; Huang S; Aihara E; ElSayed M; Aburub A
Int J Pharm; 2024 Jan; 650():123680. PubMed ID: 38070657
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C
Twarog C; Fattal E; Noiray M; Illel B; Brayden DJ; Taverna M; Hillaireau H
Int J Pharm; 2022 Oct; 626():122131. PubMed ID: 36028084
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C
Twarog C; McCartney F; Harrison SM; Illel B; Fattal E; Brayden DJ
Eur J Pharm Sci; 2021 Mar; 158():105685. PubMed ID: 33359131
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.
Kim JC; Park EJ; Na DH
Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559036
[TBL] [Abstract][Full Text] [Related]
7. Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers.
Fattah S; Ismaiel M; Murphy B; Rulikowska A; Frias JM; Winter DC; Brayden DJ
Eur J Pharm Sci; 2020 Nov; 154():105509. PubMed ID: 32777258
[TBL] [Abstract][Full Text] [Related]
8.
Tran H; Aihara E; Mohammed FA; Qu H; Riley A; Su Y; Lai X; Huang S; Aburub A; Chen JJH; Vitale OH; Lao Y; Estwick S; Qi Z; ElSayed MEH
Mol Pharm; 2023 Feb; 20(2):929-941. PubMed ID: 36592951
[TBL] [Abstract][Full Text] [Related]
9. Safety concerns over the use of intestinal permeation enhancers: A mini-review.
McCartney F; Gleeson JP; Brayden DJ
Tissue Barriers; 2016; 4(2):e1176822. PubMed ID: 27358756
[TBL] [Abstract][Full Text] [Related]
10. In Silico-Based Experiments on Mechanistic Interactions between Several Intestinal Permeation Enhancers with a Lipid Bilayer Model.
Kneiszl R; Hossain S; Larsson P
Mol Pharm; 2022 Jan; 19(1):124-137. PubMed ID: 34913341
[TBL] [Abstract][Full Text] [Related]
11. SNAC for Enhanced Oral Bioavailability: An Updated Review.
Kommineni N; Sainaga Jyothi VGS; Butreddy A; Raju S; Shapira T; Khan W; Angsantikul P; Domb AJ
Pharm Res; 2023 Mar; 40(3):633-650. PubMed ID: 36539668
[TBL] [Abstract][Full Text] [Related]
12. Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers.
Hossain S; Joyce P; Parrow A; Jõemetsa S; Höök F; Larsson P; Bergström CAS
Mol Pharm; 2020 Nov; 17(11):4226-4240. PubMed ID: 32960068
[TBL] [Abstract][Full Text] [Related]
13. Interaction between Permeation Enhancers and Lipid Bilayers.
Kang C; Bernaldez M; Stamatis SD; Rose JP; Sun R
J Phys Chem B; 2024 Feb; 128(7):1668-1679. PubMed ID: 38232311
[TBL] [Abstract][Full Text] [Related]
14. Physical and barrier changes in gastrointestinal mucus induced by the permeation enhancer sodium 8-[(2-hydroxybenzoyl)amino]octanoate (SNAC).
Mortensen JS; Bohr SS; Harloff-Helleberg S; Hatzakis NS; Saaby L; Nielsen HM
J Control Release; 2022 Dec; 352():163-178. PubMed ID: 36314534
[TBL] [Abstract][Full Text] [Related]
15. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
[TBL] [Abstract][Full Text] [Related]
16. Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability.
Chen H; Lu Y; Shi S; Zhang Q; Cao X; Sun L; An D; Zhang X; Kong X; Liu J
Pharm Res; 2022 Aug; 39(8):1891-1906. PubMed ID: 35698011
[TBL] [Abstract][Full Text] [Related]
17. Enhancing Intestinal Absorption of a Model Macromolecule via the Paracellular Pathway using E-Cadherin Peptides.
Dening TJ; Siahaan TJ; Hageman MJ
J Pharm Sci; 2021 May; 110(5):2139-2148. PubMed ID: 33359310
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Sucrose Laurate as an Intestinal Permeation Enhancer for Macromolecules: Ex Vivo and In Vivo Studies.
McCartney F; Rosa M; Brayden DJ
Pharmaceutics; 2019 Oct; 11(11):. PubMed ID: 31683652
[TBL] [Abstract][Full Text] [Related]
19. Impact of Intestinal Concentration and Colloidal Structure on the Permeation-Enhancing Efficiency of Sodium Caprate in the Rat.
Berg S; Kärrberg L; Suljovic D; Seeliger F; Söderberg M; Perez-Alcazar M; Van Zuydam N; Abrahamsson B; Hugerth AM; Davies N; Bergström CAS
Mol Pharm; 2022 Jan; 19(1):200-212. PubMed ID: 34928160
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects.
Castelli MC; Wong DF; Friedman K; Riley MG
Clin Ther; 2011 Jul; 33(7):934-45. PubMed ID: 21722960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
